Drug Discovery News, Articles, Events

Potential therapeutic target for ALS revealed
Strathmin2 could be used as a biomarker for amyotrophic lateral sclerosis (ALS), a debilitating condition with no proper diagnostic tests or treatments...
Small molecules could have big benefits in the battle against cancers
Immunotherapy and targeted treatments, including targeted chemotherapy, continue to show great potential in cancer care. Future steps in their development will involve improving their ability to treat a wider range of cancers and a broader cross-section of the patient population, especially those for whom current treatments have shown limited efficacy...
Hidden culprit in heart failure discovered
A study has identified that PI3K alpha could be the culprit of heart failure, as it binds to gelsolin, suppressing it and preventing it from working...
Stem cell study optimises bone marrow transplants
A study has shown how stem cells that are transplanted act in a different way to those ordinarily present, without a transplant...

#soliloquy-container-17517{opacity:1}#soliloquy-container-17517 li>.soliloquy-caption{display:none}#soliloquy-container-17517 li:first-child>.soliloquy-caption{display:block} Potential therapeutic target for ALS revealed

Potential therapeutic target for ALS revealed

Small molecules could have big benefits in the battle against cancers

Hidden culprit in heart failure discovered

Stem cell study optimises bone marrow transplants

Latest news

Application note: PHERAstar^® measures AlphaScreen assay to develop selective inhibitors for the human YEATS domains

Supplement

Application Notes supplement 2018

Event

4th EACR Conference on Cancer Genomics

From our latest issue...

product

Intellicyt^® T Cell Activation Cell and Cytokine Profiling Kit

Content Hub

IntelliCyt Corporation is the market leader in suspension-cell analysis platforms

Website development by e-Motive Media Limited.